The Lancet Infectious Diseases in conversation with
The Lancet Group
18 episodes
2 weeks ago
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
All content for The Lancet Infectious Diseases in conversation with is the property of The Lancet Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile
The Lancet Infectious Diseases in conversation with
15 minutes
5 months ago
Leonardo Basso and Juan Pablo Torres on the NIRSE-CL study of nirsevimab in Chile
Leonardo Basso and Juan Pablo Torres discuss their study in The Lancet Infectious Diseases on the effectiveness and impact of the first season of Chile's national immunisation programme with nirsevimab. They discuss the evidence that led to the design and implementation of the programme, its impact on RSV burden and the Chilean health system, and lessons for other countries in the region and beyond. Read the full article at: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)0...
The Lancet Infectious Diseases in conversation with
Professors Steven Tong and Joshua Davis discuss all aspects of adaptive platform trials including advantages, disadvantages, differences from conventional trials, and tips for setting up and assessing them. They also highlight several adaptive platform trials currently in the pipeline that could influence infectious disease clinical practise in the future. Click here to read our latest issue Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://ins...
